Differences in SARS ‐ CoV ‐2 Antigen Persistence in Individuals With Systemic Autoimmune Rheumatic Diseases Compared to the General Population: A RECOVER ‐Adult Cohort Study
Authors' conclusion
Individuals with SARDs were more likely to have SARS-CoV-2 antigen positivity at months 3 and 6 following COVID-19 infection compared with individuals without SARDs, not explained by demographics, variant, vaccination, or treatment.
Study context
- Population
- Individuals with and without systemic autoimmune rheumatic diseases after COVID-19
- Participants
- 210 vs 348
- Exposure
- Individuals with systemic autoimmune rheumatic diseases (SARDs) vs without SARDs
- RheumCARDn = 210
- RECOVER-Adultn = 348reference
- Outcome
- SARS-CoV-2 antigen (spike, receptor-binding domain-containing spike protein, nucleocapsid) positivity, measured by ultrasensitive single molecule array
- Follow-up
- Months 3 and 6 following COVID-19
Methodological detailslogistic regression adjusted for age, sex, infection year, vaccination status and COVID-19 treatment
- Logistic regression adjusted for age, sex, infection year, vaccination status and COVID-19 treatment
Main finding
As reported in the abstract
Any SARS-CoV-2 antigen positivity
P < 0.001
Observational data: associations, not effects.
Further findings
| Outcome | aOR (95% CI) | |
|---|---|---|
| Nucleocapsid antigen positivity · 3 months | 3.73 (1.28–10.85) | |
| Any antigen positivity · 3 months | 2.89 (1.43–5.85) | |
| Nucleocapsid antigen positivity · 6 months | 6.62 (1.09–40.30) | |
| 0.050.21520Adjusted odds ratio (log scale) |
Original publication
Differences in SARS ‐ CoV ‐2 Antigen Persistence in Individuals With Systemic Autoimmune Rheumatic Diseases Compared to the General Population: A RECOVER ‐Adult Cohort Study. Arthritis Rheumatol. Published 27 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →